Abstract
Arterial hypertension (AH) and obesity are among the six most important risk factors leading to death in the world. Both risk factors increase the risk not only of cardiovascular disease, but also the risk of cancer and chronic kidney disease.
There are close two-way links between obesity and AH. Obesity increases the risk of developing AH two to threefold and in obese patients, blood pressure control is more difficult to achieve.
On the other hand, a positive family history of AH predicts development of central obesity. At the same time, people with higher blood pressure have a higher risk of weight gain than people with lower blood pressure.
The central motif of blood pressure elevation in obesity is increased sodium and water retention due to renin-angiotensin system activation and increased sympathetic activity. Recent analysis of data from real practice points to efficiency and safety and metabolic neutrality of the fixed combination Perindopril/Indapamide in subjects with AH and obesity, type 2 diabetes mellitus or metabolic syndrome.